Enokizumab
Enokizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It specifically targets the interleukin-6 (IL-6) pathway, which plays a crucial role in the inflammatory response associated with various autoimmune conditions.
Mechanism of Action[edit | edit source]
Enokizumab functions by binding to the IL-6 receptor, thereby inhibiting the interaction of IL-6 with its receptor. This blockade prevents the downstream signaling that leads to inflammation and tissue damage. IL-6 is a cytokine involved in the immune response, and its dysregulation is implicated in diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease.
Clinical Applications[edit | edit source]
Enokizumab is primarily used in the management of chronic inflammatory conditions. Its efficacy has been demonstrated in clinical trials for the treatment of:
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Enokizumab includes its absorption, distribution, metabolism, and excretion. It is typically administered via subcutaneous injection, allowing for direct entry into the bloodstream. The drug has a half-life that supports dosing every two to four weeks, depending on the condition being treated.
Adverse Effects[edit | edit source]
Common adverse effects associated with Enokizumab include:
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Elevated liver enzymes
Serious adverse effects may include increased risk of infections due to immunosuppression, and rare cases of gastrointestinal perforation.
Regulatory Status[edit | edit source]
Enokizumab has been approved by regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific indications. Ongoing studies are evaluating its use in other autoimmune conditions.
Research and Development[edit | edit source]
Research is ongoing to explore additional therapeutic applications of Enokizumab, including its potential use in oncology and other inflammatory disorders. Studies are also investigating the long-term safety and efficacy of the drug.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
